SAN DIEGO, March 7, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Dr. Shailender Bhatia, Principal Investigator for the company's Phase II Merkel cell carcinoma clinical trial, was featured in a local Seattle news outlet, The Journal Newspaper.
The article, titled "Fighting skin cancer with electroimmunotherapy," outlines the rationale for the Phase II Merkel cell carcinoma study and describes the urgent need for a new therapy for this patient population.
To read the article in its entirety, please visit the following link:
In related news, the University of Washington and OncoSec were also featured in a news segment by the Seattle NBC affiliate news agency, KIRO 7. The video for this news story can be viewed here.
About Merkel Cell Carcinoma
Merkel cell carcinoma (MCC), sometimes referred to as a neuroendocrine carcinoma of the skin, arises from the uncontrolled growth of Merkel cells in the skin. It is a rare skin cancer with roughly 1,500 cases per year in the United States, making it about 40 times less common than melanoma. More significantly, it is three times more lethal, thus prompt aggressive treatment is warranted. The majority of Merkel cell carcinomas appear to be caused in part by a virus, Merkel cell polyomavirus. Because greater than 80% of patients with MCC carry the Merkel cell polyomavirus, it is believed that an immunotherapy which stimulates the immune system to recognize and kill the virus and cancer may be a beneficial therapy for this patient population.
About OncoSec's Merkel Cell Carcinoma Phase II Study (OMS-I110)
The University of Washington, in conjunction with the Fred Hutchinson Cancer Center, is the leading site for OncoSec's Phase II study for the treatment Merkel cell carcinoma. In this study the Company's OMS ElectroImmunotherapy technology is being used to stimulate the immune system to recognize and attack cancer cells. A total of up to 15 patients with local and distant Merkel cell carcinoma will be enrolled in this Phase II, single-arm, open-label, multi-center study. The trial is designed to assess the clinical and biologic effects of increased local expression of IL-12 protein in the tumor microenvironment following treatment with OMS ElectroImmunotherapy. It is anticipated that marked local expression of IL-12 in the tumor will induce an immunologic response in the tumor microenvironment, which may result in clinical benefit for the patient. To date, several patients have been enrolled in this study, and preliminary data is expected to be released before the end of 2012.
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Incorporated